Chennai pharma maker of generics, branded generics & injectables sold across Latin America, Africa and the US.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 858 | 954 | 1.3k | 1.6k | 2.1k | 2.6k | 3.1k | 3.6k |
| Borrowings | 113 | 235 | 219 | 222 | 219 | 222 | 5 | 5 |
| Other Liabilities | 139 | 159 | 250 | 305 | 380 | 352 | 339 | 454 |
| Total Liabilities | 1.1k | 1.4k | 1.7k | 2.2k | 2.7k | 3.2k | 3.5k | 4.0k |
| AssetsFixed Assets | 272 | 305 | 287 | 280 | 453 | 546 | 555 | 605 |
| CWIP | 20 | 14 | 18 | 221 | 117 | 144 | 177 | 209 |
| Investments | 61 | 11 | 89 | 281 | 376 | 590 | 636 | 859 |
| Other Assets | 772 | 1.0k | 1.3k | 1.4k | 1.8k | 1.9k | 2.1k | 2.4k |
| Total Assets | 1.1k | 1.4k | 1.7k | 2.2k | 2.7k | 3.2k | 3.5k | 4.0k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Cash from Investing | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 |
| Cash from Financing | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (23.4×) and current (29.7×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 20% growth and a 23× exit, ₹2504 only delivers your return if you pay ₹2,174. The price is currently baking in 23% growth.
EPS grows 20%/yr for 5 years, then fades to 6% over 2, exits at 23×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 20.0% | 101.23 |
| FY28 | 20.0% | 121.48 |
| FY29 | 20.0% | 145.77 |
| FY30 | 20.0% | 174.93 |
| FY31 | 20.0% | 209.91 |
| FY32 | 13.0% ·fade | 237.20 |
| FY33 | 6.0% ·fade | 251.44 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.